相关实验视频
Updated: May 31, 2025

08:50
Assessment of Vascular Function in Patients With Chronic Kidney Disease
Published on: June 16, 2014
16.2K
罗沙沙斯塔特在患有慢性病的患者中的有效性和安全性:根据基线炎症状况进行聚合分析
Gabriel Choukroun1, Frank Strutz2, Alexander Harkavyi3
1Nephrology Dialysis Transplantation Department, CHU Amiens Picardie and Jules Verne University, 80000 Amiens, France.
Journal of clinical medicine
|January 25, 2025
概括
在慢性病 (CKD) 患者中,Roxadustat有效治疗贫血,无论炎症水平如何. 这种贫血治疗不需要调整剂量,即使是在高度炎症的患者中,与红色素形成刺激剂 (ESAs) 不同.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 血液学 血液学 血液学
- 药理学 药理学是指药理学的学科.
背景情况:
- 炎症是慢性病 (CKD) 的常见并发症,可能导致对红色素形成刺激剂 (ESAs) 的低反应性.
- 罗沙杜沙特是治疗慢性脏病贫血的批准药物.
- 了解roxadustat在患有不同程度炎症的慢性病患者的疗效和安全性至关重要.
研究的目的:
- 评估与ESA相比,roxadustat在透析依赖 (DD) 和非透析依赖 (NDD) 慢性结核病患者中的疗效和安全性.
- 评估基线炎症状况的影响,以高灵敏度C反应蛋白 (hsCRP) 水平来表示,对治疗结果的影响.
- 为了确定roxadustat是否需要在炎症较高的患者中调整剂量.
主要方法:
- 一项对5项临床研究的综合分析,比较了NDD和DDCKD群体中的roxadustat和ESA.
- 血红蛋白水平和药物剂量根据基线hsCRP水平进行评估,分为五分之一.
- 安全性数据,包括治疗出现的不良事件,被描述性地总结.
主要成果:
- 罗沙杜沙特在提高血红蛋白水平方面表现出与ESA相比较的有效性,不论基线炎症如何.
- 在第24周,罗沙杜沙特剂量保持稳定,即使在基线高hsCRP水平的患者中也是如此.
- 较高的基线hsCRP水平需要增加ESA剂量,而roxadustat在没有剂量升级的情况下显示出一致的有效性.
结论:
- 罗沙沙斯塔特有效地控制了不同炎症状态的CKD贫血.
- 该药物可以治疗多种贫血原因,而不需要根据炎症调整剂量.
- 罗沙杜沙特为CKD贫血提供了一种一致的治疗选择,无论患者的炎症标志物如何.
相关概念视频
Factors Affecting Renal Clearance: Renal Impairment
48
Renal dysfunction significantly impairs the renal clearance of drugs, leading to potential complications in drug therapy. Renal failure, which can be caused by various factors, poses a significant challenge in the elimination of drugs from the body.
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
48
Renal Failure: Dose Adjustments
61
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
61
Hormonal Regulation
32.9K
The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
32.9K
Factors Affecting Renal Clearance: Drug Distribution and Drug Interactions
86
Renal clearance plays a pivotal role in drug elimination from the body and can be influenced by drug distribution and interactions. Understanding these factors is crucial in pharmacology as they impact the effectiveness and duration of drug therapy.
One important factor is the relationship between renal clearance and the apparent volume of distribution. Renal clearance tends to be inversely proportional to the apparent volume of distribution. Drugs with an extensive distribution volume or those...
One important factor is the relationship between renal clearance and the apparent volume of distribution. Renal clearance tends to be inversely proportional to the apparent volume of distribution. Drugs with an extensive distribution volume or those...
86
The JAK-STAT Signaling Pathway
8.6K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.6K

